Cybin Inc.

Equities

HELP

CA23256X4075

Market Closed - Nasdaq Other stock markets 04:00:00 2026-01-16 pm EST			5-day change	1st Jan Change
7.740 ^USD	-1.40%		+2.79%	-5.38%

Jan. 05	Cybin Inc.(NasdaqGM:HELP) added to NASDAQ Composite Index	CI
Jan. 05	Helus Pharma begins Nasdaq trading, advances mental health therapies	RE

Transcript : Cybin Inc., Q2 2026 Earnings Call, Nov 13, 2025

Published on 11/13/2025 at 03:05 pm EST - Modified on 11/18/2025 at 10:55 am EST

S&P Capital IQ

Presentation Operator Message
Operator (Operator)

Good morning, and thank you for joining the Cybin Second Quarter 2026 Financial Results and Corporate Update Call. As a reminder, our press release

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Cybin Inc.

Jan. 05	Cybin Inc.(NasdaqGM:HELP) added to NASDAQ Composite Index	CI
Jan. 05	Helus Pharma begins Nasdaq trading, advances mental health therapies	RE
Jan. 05	Cybin to Begin Nasdaq Trading Under New Ticker, Plans to Change Name to Helus Pharma	MT
Jan. 04	Cybin Inc. Primary Exchange Listing will Change to (Nasdaq Global Market: HELP) from (NYSE American LLC: CYBN)	CI
Dec. 30	Cybin Launches $100 Million At-The-Market Equity Program	MT
Dec. 18	Cybin to Transfer Listing to Nasdaq From NYSE American	MT
Dec. 18	Alerts, brief on Cybin transferring US listing to Nasdaq withdrawn	RE
Nov. 13	Cybin Inc., Q2 2026 Earnings Call, Nov 13, 2025
Nov. 13	Cybin Inc. Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2025	CI
Nov. 04	Compass Pathways to expedite launch of its experimental depression therapy	RE
25-10-31	Cybin Closes $175 Million Direct Offering	MT
25-10-28	Cybin announces $175 million registered direct offering	RE
25-09-23	Cybin Inc. Highlights Upcoming Clinical Milestones	CI
25-09-17	Cybin cuts size of mixed shelf offering - SEC filing	RE
25-09-08	Cybin Inc. Completes Enrollment in Phase 2 Study Evaluating CYB004 for the Treatment of Generalized Anxiety Disorder	CI
25-09-08	Cybin completes phase 2 enrollment evaluating CYB004 for the treatment of generalized anxiety disorder	RE
25-09-02	Cybin Inc. Announces Chief Executive Officer Changes	CI
25-09-02	Cybin Chief Executive Doug Drysdale Steps Down; Eric So Named Interim CEO	MT
25-09-02	Cybin announces senior leadership changes	RE
25-08-26	Sector Update: Health Care Stocks Edge Higher Premarket Tuesday	MT
25-08-26	Cybin Gets Approval for Major Depressive Disorder Treatment Study Evaluating CYB003 in Australia	MT
25-08-26	Cybin Inc. Receives Australian Approval for EMBRACE, a Multinational Pivotal Study Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder	CI
25-08-25	AbbVie targets psychedelic-based depression drug market with $1.2 billion deal	RE
25-08-18	Cybin Inc. Announces George Tziras Not Standing for Re-Election	CI
25-08-18	Cybin Inc. - Shareholder/Analyst Call